IGM Biosciences, Inc. (IGMS)

10.07 +0.64 (+6.79%) 收市：04:00PM EDT

IGM Biosciences, Inc.

325 East Middlefield Road
Mountain View, CA 94043
United States
650 965 7873
https://igmbio.com

版塊: Healthcare
行業: Biotechnology
全職員工: 224

高階主管

名稱	頭銜	支付	行使價	出生年份
Mr. Fred M. Schwarzer J.D.	CEO, President & Director	1M	無	1953
Dr. Bruce A. Keyt Ph.D.	Chief Scientific Officer	713.78k	無	1953
Dr. Chris H. Takimoto FACP, M.D., Ph.D.	Chief Medical Officer	705.39k	無	1959
Mr. Misbah Tahir	Chief Financial Officer	957.6k	無	1975
Mr. TS Harigopal	Senior Vice President of Group Operations	無	無	無
Mr. Paul C. Graffagnino	Senior Vice President of Legal Affairs	無	無	無
Ms. Suzette Tauber	Chief Human Resources Officer	無	無	1964
Dr. Angus M. Sinclair Ph.D.	Senior Vice President of Immuno-Oncology	無	無	無
Dr. Lisa L. Decker Ph.D.	Chief Business Officer	528.18k	無	1970
Dr. Marvin S. Peterson Ph.D.	Executive Vice President of Process Development & Manufacturing	無	無	無

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

IGM Biosciences, Inc., a clinical-stage biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer and autoimmune and inflammatory diseases. It develops Aplitabart, a Death Receptor 5 Agonist IgM antibody for the treatment of colorectal cancer; imvotamab, a CD20 x CD3 bispecific IgM antibody to treat myositis, as well as for the treatment of systemic lupus erythematosus and rheumatoid arthritis that is Phase Ib clinical trial; and IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of autoimmune diseases. IGM Biosciences, Inc. has a collaboration and license agreement with Genzyme Corporation to generate, develop, manufacture, and commercialize IgM antibodies. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.

公司管治

截至 2024年5月1日 止，IGM Biosciences, Inc. 的 ISS 管治質素評分為 10。 Pillar 分數正在審核中：8；董事會：9；股東權利：10；現金賠償：9。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。